GlassScriptPhysician profile
Jonathon M Blais
NPI 1881048213
$3,776.03
in general payments reported to CMS, 2019-2025
21 companies · $1,298 in 2025
The $1,298 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $326 · 2020: $494 · 2021: $355 · 2022: $505 · 2023: $490 · 2024: $308 · 2025: $1,298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,759 · Travel and Lodging: $336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,759.09 |
| Travel and Lodging | $336.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $950.77 | 2022-2025 | Watchman Access System, Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $823.20 | 2019-2025 | Lifevest |
| Biotronik INC. | $370.00 | 2020 | |
| Abbott Laboratories | $359.00 | 2021-2025 | Jot Dx, Aveir, Thoratec Heartmate 3 Lvas Implant Kit |
| Novartis Pharmaceuticals Corporation | $267.23 | 2023-2025 | |
| Pfizer INC. | $154.19 | 2024-2025 | |
| Abiomed | $119.09 | 2022 | |
| Amgen INC. | $100.99 | 2023-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $86.21 | 2022-2024 | Andexxa |
| E.R. Squibb & Sons, L.L.C. | $82.91 | 2022-2025 | Camzyos |
| Janssen Pharmaceuticals, INC | $81.20 | 2022-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.31 | 2025 | Jardiance |
| Biosense Webster, INC. | $70.79 | 2019 | |
| Medtronic, INC. | $57.11 | 2022 | |
| Merck Sharp & Dohme LLC | $38.02 | 2023-2024 | Verquvo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $32.16 | 2023 | Opsumit |
| Baxter Healthcare | $29.27 | 2023-2024 | Hillrom - Cardiac Ambulatory Monitor |
| Philips North America LLC | $25.43 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $21.04 | 2024 | Arcalyst |
| Bridgebio Pharma, INC. | $17.72 | 2025 | Attruby |
| Livanova USA, INC. | $14.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathon Blais listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.